The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 297.00
Bid: 290.00
Ask: 304.00
Change: 0.00 (0.00%)
Spread: 14.00 (4.828%)
Open: 297.00
High: 297.00
Low: 297.00
Prev. Close: 297.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HC Wainright & Co Virtual Conference Presentation

10 Sep 2020 07:00

RNS Number : 5403Y
MaxCyte, Inc.
10 September 2020
 

 

 

MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co

22nd Annual Global Investment Virtual Conference

 

 

GAITHERSBURG, MD, 10 September 2020 - MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announced that CEO Doug Doerfler plans to present an overview of the company at the upcoming H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020. Details are as follows:

 

Presentation Date/Time: Monday, September 14, at 4:00 p.m. EDT

Online access: https://wsw.com/webcast/hcw7/maxcyte/2019107

 

 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com .

 

 

Contacts:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer

 

+1 301-944-1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

Rupert Dearden

 

 

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith

 

 

+44 (0)20 7260 1000

 

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Ashley Tapp

 

--------------------------------------------------------------

 

+44 (0)203 709 5700

maxcyte@consilium-com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAKKCBNOBKDBCK
Date   Source Headline
23rd Oct 20197:01 amRNSPresentations at Cell & Gene Therapy Congress
8th Oct 20197:00 amRNSNotification of AGM and Audit Declaration
7th Oct 20197:00 amRNSEditas Clinical and Commercial License Agreement
30th Sep 20197:00 amRNSUpdates on CARMA Platform at Upcoming Meetings
18th Sep 20197:00 amRNSResults for the Six Months ended 30 June 2019
9th Sep 20197:00 amRNSPresentation at ICLE 2019
14th Aug 20197:00 amRNSNotice of Results
17th Jul 20197:00 amRNSTrading Update
11th Jul 20197:00 amRNSMaxCyte to Host Capital Markets Day Today
5th Jul 20194:42 pmRNSSecond Price Monitoring Extn
5th Jul 20194:36 pmRNSPrice Monitoring Extension
19th Jun 20197:00 amRNSAnnual Report
12th Jun 20197:00 amRNSAppointment of Joint Corporate Broker
29th May 20197:00 amRNSSave the Date: Capital Markets Day
8th May 20194:41 pmRNSSecond Price Monitoring Extn
8th May 20194:36 pmRNSPrice Monitoring Extension
8th May 20197:00 amRNSPhase I Clinical Trial of MCY-M11 Progressed
1st May 20197:00 amRNSASGCT Presentation on First CARMA Drug Candidate
24th Apr 20197:00 amRNSFinal Results for Year Ended 31 December 2018
8th Apr 20197:00 amRNSLaunch of ExPERTT Instrument Family
26th Mar 20197:00 amRNSNotice of Full Year Results
19th Mar 20195:05 pmRNSDirector Dealings
5th Mar 20197:00 amRNSGrant of Options
1st Mar 20197:00 amRNSClinical & Commercial Agreement with Kite
26th Feb 20195:32 pmRNSResult of Special Meeting and Issue of Equity
5th Feb 20194:32 pmRNSResults of Placing
5th Feb 20197:00 amRNSProposed Placing to raise a minimum of £10 million
15th Jan 20197:00 amRNSTrading Update
19th Dec 20187:00 amRNSChange of Auditor
17th Dec 20186:06 pmRNSDirector Dealings
21st Nov 20187:00 amRNSConsolidation of Trading Lines
20th Nov 20187:00 amRNSBlock Admission Six Monthly Return/TVR
16th Nov 20187:00 amRNSWebinar: non-viral cell engineering
14th Nov 20187:00 amRNSClinical and Commercial License Agreement
12th Nov 20187:00 amRNSMaxCyte Announces Research Agreement with Kite
9th Nov 20187:00 amRNSExpansion of CRISPR Commercial License Agreement
31st Oct 20184:25 pmRNSResult of AGM
10th Oct 20187:00 amRNSDosing Begins in First Clinical Trial of MCY-M11
8th Oct 20187:00 amRNSNotice of AGM
24th Sep 20187:00 amRNSResults for the Half Year ended 30 June 2018
10th Sep 20187:00 amRNSGrant of Options
3rd Sep 20187:00 amRNSNotice of Half Year Results
26th Jul 20185:33 pmRNSDirector/PDMR Shareholding
16th Jul 20187:00 amRNSFDA IND Clearance for First Clinical Programme
16th Jul 20187:00 amRNSTrading Update
11th Jun 20187:00 amRNSMaxCyte & NIH enter CRADA for Sickle Cell Disease
21st May 20187:00 amRNSPreclinical Results at ASGCT Annual Meeting
30th Apr 20187:00 amRNSNotice of AGM and Annual Report
25th Apr 20187:00 amRNSCMO Appointment
4th Apr 20187:00 amRNSFinal Results for Year Ended 31 December 2017

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.